Sandoz China: Do we stay or do we go?
The Sandoz leadership team faced an important decision as it broke away from Novartis and became a public company. Should Sandoz retain the global geographical coverage it had had in its many years as part of Novartis? Or should it focus on fewer geographies and a simplification of the business models it was using? Since Sandoz was in a lower margin business than an innovator pharma company like Novartis, eventually, the senior leadership team decided to exit China. There was a belief that it was going to be difficult to compete on price with local Chinese companies, and the investment required to invest in more complex generics, as well as high-margin biosimilars, was beyond the means of Sandoz as it became a publicly listed company. The case also touches on the differences of opinion in a very strong leadership team and the options that were explored, or not, as the sale of Sandoz China to Aspen Pharmacare was concluded.
- Understand the extreme stress of a leadership team attempting to make myriad decisions in an unfavorable market environment.
- Understand that strategy means choice – a company cannot do everything it wishes.
- Evaluate an exit decision versus continued investment, considering both quantitative factors (market size, growth and profitability) and qualitative factors (strategic alignment, reputation and people impact).
- Develop a sense of the differing opinions and objectives of the members of the leadership team and their ability to perform a multifaceted strategic analysis under uncertainty.
Sandoz, Healthcare, Pharmaceuticals
2023
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Businesses are adopting artificial intelligence at pace, and spending heavily to do so. Big Tech alone plans to invest more than US$660 billion (S$844 billion) in 2026. But for most companies, spending is running ahead of visible returns. A flood ...
To some, Apple is starting to look like a company on the back foot. The appointment of Mr John Ternus, a long-time hardware chief, to CEO only sharpens the question of whether the US$4 trillion (S$5 trillion) company can keep pace in artificial in...
Ask a roomful of executives whether their company takes sustainability seriously, and almost every hand goes up. But ask whether their sustainability investments are generating real commercial returns, and the room may get quieter. The gap between...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications